These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 3781102)

  • 1. Communication within families about Duchenne muscular dystrophy.
    Fitzpatrick C; Barry C
    Dev Med Child Neurol; 1986 Oct; 28(5):596-9. PubMed ID: 3781102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reactions of families to children with Duchenne muscular dystrophy.
    Buchanan DC; LaBarbera CJ; Roelofs R; Olson W
    Gen Hosp Psychiatry; 1979 Sep; 1(3):262-9. PubMed ID: 499799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cultural differences in family communication about Duchenne muscular dystrophy.
    Fitzpatrick C; Barry C
    Dev Med Child Neurol; 1990 Nov; 32(11):967-73. PubMed ID: 2269406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interviews with parents of boys suffering from Duchenne muscular dystrophy.
    Firth M; Gardner-Medwin D; Hosking G; Wilkinson E
    Dev Med Child Neurol; 1983 Aug; 25(4):466-71. PubMed ID: 6618025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psychiatric disorder among boys with Duchenne muscular dystrophy.
    Fitzpatrick C; Barry C; Garvey C
    Dev Med Child Neurol; 1986 Oct; 28(5):589-95. PubMed ID: 3781101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Duchenne muscular dystrophy--parental perceptions.
    Bothwell JE; Dooley JM; Gordon KE; MacAuley A; Camfield PR; MacSween J
    Clin Pediatr (Phila); 2002 Mar; 41(2):105-9. PubMed ID: 11931326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parent-child communication and timing of interventions are challenges in the Duchenne muscular dystrophy care.
    Saetrang T; Bjørk IT; Capjon H; Rasmussen M
    Acta Paediatr; 2019 Mar; 108(3):535-540. PubMed ID: 30118557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic risk: women's understanding of carrier risks in Duchenne muscular dystrophy.
    Parsons EP; Clarke AJ
    J Med Genet; 1993 Jul; 30(7):562-6. PubMed ID: 8411028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Family communication about genetic risk information: particular issues for Duchenne muscular dystrophy.
    Plumridge G; Metcalfe A; Coad J; Gill P
    Am J Med Genet A; 2010 May; 152A(5):1225-32. PubMed ID: 20425827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of Duchenne muscular dystrophy carriers by dosage analysis using the DMD cDNA clone 8.
    Mao YP; Cremer M
    Hum Genet; 1989 Jan; 81(2):193-5. PubMed ID: 2912889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The incidence of Duchenne muscular dystrophy in eastern Austria. The controversy regarding CK screening.
    Hauser E; Toifl K; Mad A; Bittner R
    Wien Klin Wochenschr; 1993; 105(15):433-6. PubMed ID: 8104369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythrocyte spectrofluorometric abnormalities in Duchenne patients and carriers. A new approach to carrier detection.
    Scarlato G; Meola G; Silani V; Manfredi L; Bottiroli G; Zanella A
    Acta Neurol Scand; 1979 May; 59(5):262-9. PubMed ID: 474067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delay in diagnosing Duchenne muscular dystrophy in orthopaedic clinics.
    Read L; Galasko CS
    J Bone Joint Surg Br; 1986 May; 68(3):481-2. PubMed ID: 3733820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carrier testing in families of isolated cases of duchenne muscular dystrophy. Creatine kinase activities in female relatives of mothers with normal CK activity.
    Nicholson GA; Lane RJ; Gardner-Medwin D; Walton JN
    J Neurol Sci; 1981 Jul; 51(1):29-42. PubMed ID: 7252519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parental group therapy in the management of two fatal childhood diseases: a comparison.
    Kornfeld MS; Siegel IM
    Health Soc Work; 1980 Nov; 5(4):28-34. PubMed ID: 7203254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The significance of different types of information in calculating the probability that a female relative of a Duchenne muscular dystrophy patient is a carrier.
    ten Kate LP; Offringa PJ
    Clin Genet; 1981 Oct; 20(4):281-8. PubMed ID: 7333021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identifying Non-Duchenne Muscular Dystrophy-Positive and False Negative Results in Prior Duchenne Muscular Dystrophy Newborn Screening Programs: A Review.
    Gatheridge MA; Kwon JM; Mendell JM; Scheuerbrandt G; Moat SJ; Eyskens F; Rockman-Greenberg C; Drousiotou A; Griggs RC
    JAMA Neurol; 2016 Jan; 73(1):111-6. PubMed ID: 26594870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimates of conditional heterozygosity risks for young females in Duchenne muscular dystrophy.
    Passos-Bueno MR; Otto PA; Zata M
    Hum Hered; 1989; 39(4):202-11. PubMed ID: 2583732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased chloride efflux in fibroblasts from X-linked muscular dystrophies and clones from Duchenne carriers.
    Rugolo M; Rocchi M; Lenaz G; Romeo G
    FEBS Lett; 1987 Feb; 212(2):313-6. PubMed ID: 3817163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Duchenne muscular dystrophy: high frequency of deletions.
    Bartlett RJ; Pericak-Vance MA; Koh J; Yamaoka LH; Chen JC; Hung WY; Speer MC; Wapenaar MC; Van Ommen GJ; Bakker E
    Neurology; 1988 Jan; 38(1):1-4. PubMed ID: 3275902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.